AJP - Renal AJP: Cell Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol 291: F1021-F1032, 2006. First published June 6, 2006; doi:10.1152/ajprenal.00387.2005
0363-6127/06 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
291/5/F1021    most recent
00387.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jensen, A. M.
Right arrow Articles by Frøkiær, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jensen, A. M.
Right arrow Articles by Frøkiær, J.

Angiotensin II mediates downregulation of aquaporin water channels and key renal sodium transporters in response to urinary tract obstruction

Anja M. Jensen,1,2 Chunling Li,1,2 Helle A. Praetorius,1,2 Rikke Nørregaard,1,2 Sebastian Frische,1 Mark A. Knepper,4 Søren Nielsen,1,3 and Jørgen Frøkiær1,2

1The Water and Salt Research Center, 2Institute of Clinical Medicine, and 3Institute of Anatomy, University of Aarhus, Aarhus, Denmark; and 4Laboratory of Kidney and Electrolyte Metabolism, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland

The renin-angiotensin system is well known to be involved in the pathophysiological changes in renal function after obstruction of the ureter. Previously, we demonstrated that bilateral ureteral obstruction (BUO) is associated with dramatic changes in the expression of both renal sodium transporters and aquaporin water channels (AQPs). We now examined the effects of the AT1-receptor antagonist candesartan on the dysregulation of AQPs and key renal sodium transporters in rats subjected to 24-h BUO and followed 2 days after release of BUO (BUO-2R). Consistent with previous observations, BUO-2R resulted in a significantly decreased expression of AQP1, -2, and -3 compared with control rats. Concomitantly, the rats developed polyuria and reduced urine osmolality. Moreover, expression of the type 2 Na-phosphate cotransporter (NaPi-2) and type 1 bumetanide-sensitive Na-K-2Cl cotransporter (NKCC2) was markedly reduced, consistent with postobstructive natriuresis. Candesartan treatment from the onset of obstruction attenuated the reduction in GFR (3.1 ± 0.4 vs. 1.7 ± 0.3 ml·min–1·kg–1) and partially prevented the reduction in the expression of AQP2 (66 ± 21 vs. 13 ± 2%, n = 7; P < 0.05), NaPi-2 (84 ± 6 vs. 57 ± 10%, n = 7; P < 0.05), and NKCC2 (89 ± 12 vs. 46% ± 11, n = 7; P < 0.05). Consistent with this, candesartan treatment attenuated the increase in urine output (58 ± 4 vs. 97 ± 5 µl·min–1·kg–1, n = 7; P < 0.01) and the reduction in sodium reabsorption (433 ± 62 vs. 233 ± 45 µmol·min–1·kg–1, n = 7; P < 0.05) normally found in rats subjected to BUO. Moreover, candesartan treatment attenuated induction of cyclooxygenase 2 (COX-2) expression in the inner medulla, suggesting that COX-2 induction in response to obstruction is regulated by ANG II. In conclusion, candesartan prevents dysregulation of AQP2, sodium transporters, and development of polyuria seen in BUO. This strongly supports the view that candesartan protects kidney function in response to urinary tract obstruction.

aquaporins; angiotensin; AT1-receptor blockade



Address for reprint requests and other correspondence: J. Frøkiær, The Water and Salt Research Center, Univ. of Aarhus, Institute of Clinical Medicine/Dept. of Clinical Physiology, Aarhus Univ. Hospital, Brendstrupgaardsvej, DK-8200 Aarhus N., Denmark (e-mail: JF{at}KI.AU.DK)




This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
M. H. M. Shimizu, A. Danilovic, L. Andrade, R. A. Volpini, A. B. Liborio, T. R.C. Sanches, and A. C. Seguro
N-acetylcysteine protects against renal injury following bilateral ureteral obstruction
Nephrol. Dial. Transplant., May 9, 2008; (2008) gfn237v1.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
V. K. Madala Halagappa, S. Tiwari, S. Riazi, X. Hu, and C. M. Ecelbarger
Chronic candesartan alters expression and activity of NKCC2, NCC, and ENaC in the obese Zucker rat
Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1222 - F1231.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. B. Sandberg, A. D. M. Riquier, K. Pihakaski-Maunsbach, A. A. McDonough, and A. B. Maunsbach
ANG II provokes acute trafficking of distal tubule Na+-Cl cotransporter to apical membrane
Am J Physiol Renal Physiol, September 1, 2007; 293(3): F662 - F669.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
C. M. Coleman, J. J. Minor, L. E. Burt, B. A. Thornhill, M. S. Forbes, and R. L. Chevalier
Angiotensin AT1-receptor inhibition exacerbates renal injury resulting from partial unilateral ureteral obstruction in the neonatal rat
Am J Physiol Renal Physiol, July 1, 2007; 293(1): F262 - F268.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
S. O. Topcu, M. Pedersen, R. Norregaard, G. Wang, M. Knepper, J. C. Djurhuus, S. Nielsen, T. M. Jorgensen, and J. Frokiaer
Candesartan prevents long-term impairment of renal function in response to neonatal partial unilateral ureteral obstruction
Am J Physiol Renal Physiol, February 1, 2007; 292(2): F736 - F748.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.